Dr. Reddy's Laboratories Limited (RDY)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below the required floor of 3); the upstream qualitative screen flagged the name (in-window sentiment deterioration, no bullish catalyst) and the strategy requires qualitativeScore ≥ 3 before any bullish entry — the shadow sum-gate flag is false, so no SHADOW paper plan is emitted.
Company overview
Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in Hyderabad, India. It operates through segments such as Global Generics, which produces prescription and over-the-counter drugs, and Pharmaceutical Services and Active Ingredients, which manufactures APIs and chemical intermediates. The company also engages in proprietary product development and has a partnership with Curis, Inc. for oncology research.
Fundamental
fairSolid balance sheet and growth, but margin compression and regulatory risks create uncertainty.
Financially robust Indian generics ADR with a fortress balance sheet, strong operating cash flow and a defensive beta — but in a confirmed earnings downturn: US revenue fell 22% in FY2026 and another 35% in Q1 FY2027 on Lenalidomide price erosion, TTM EPS is down over 40%, and the stock still trades around 30x trailing earnings with a ~1.5% free-cash-flow yield. Mixed fundamentals: the balance sheet is the floor, the profit trajectory and valuation are the headwinds.
Sentiment
weakMedia sentiment is negative, and no positive catalysts are present.
Bearish-tilted setup: a fresh USFDA two-observation finding at the Mexico API facility (announced, 2026-09-12) and the still-unresolved semaglutide supply-halt remediation dominate the 1–30 day map, with a determinate negative media delta (baseline ≈ −0.039 → scoring ≈ −0.166) and no offsetting bullish catalyst; moderate red-flag cap applied (in-window sentiment deterioration with no offsetting bullish catalyst).
Technical
weakPrice is below major moving averages with strong downtrend signals.
Bearish/broken structure: RDY trades below its entire moving-average stack (SMA20 12.05, EMA9 11.87, EMA21 12.02, SMA50 12.28, SMA200 13.40) with ADX14 33.78 confirming a strong downtrend, and MACD is below zero and still falling (line -0.16, signal -0.13, histogram -0.03). RSI14 31.51 and Williams %R -95.12 are oversold, so a short-term reflex bounce is possible, but there is no momentum confirmation to buy against the trend. Today's session closed -2.12% at 11.55, just above the 52-week low of 11.36. Independently of chart quality, the trade is suppressed by the qualitative hard block (qualitativeScore 2 < 3), so setupType is no_setup and no entry is sized.
You’re looking at 2026-09-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.